Maple Capital Management Inc. boosted its stake in shares of Thermo Fisher Scientific Inc (NYSE:TMO) by 26.9% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,137 shares of the medical research company’s stock after buying an additional 453 shares during the period. Maple Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $328,000 at the end of the most recent quarter.
Other institutional investors have also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. increased its position in Thermo Fisher Scientific by 0.3% in the first quarter. Independent Portfolio Consultants Inc. now owns 730 shares of the medical research company’s stock valued at $112,000 after buying an additional 2 shares during the last quarter. First Command Bank bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $125,000. Advantage Investment Management LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at $125,000. Cable Hill Partners LLC increased its position in Thermo Fisher Scientific by 27.1% in the third quarter. Cable Hill Partners LLC now owns 961 shares of the medical research company’s stock valued at $152,000 after buying an additional 205 shares during the last quarter. Finally, Ancora Advisors LLC acquired a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $176,000. 86.89% of the stock is owned by hedge funds and other institutional investors.
Thermo Fisher Scientific Inc (TMO) opened at 174.86 on Friday. Thermo Fisher Scientific Inc has a 12 month low of $139.07 and a 12 month high of $176.85. The stock’s 50 day moving average price is $172.39 and its 200 day moving average price is $156.39. The firm has a market capitalization of $68.41 billion, a P/E ratio of 31.90 and a beta of 1.05.
Thermo Fisher Scientific (NYSE:TMO) last posted its quarterly earnings data on Wednesday, April 26th. The medical research company reported $2.08 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $2.02 by $0.06. The firm had revenue of $4.77 billion during the quarter, compared to the consensus estimate of $4.68 billion. Thermo Fisher Scientific had a net margin of 11.58% and a return on equity of 15.73%. The business’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.80 EPS. On average, analysts forecast that Thermo Fisher Scientific Inc will post $9.22 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Monday, July 17th. Shareholders of record on Thursday, June 15th will be issued a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a yield of 0.34%. The ex-dividend date of this dividend is Tuesday, June 13th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.95%.
A number of equities research analysts have recently commented on the company. Deutsche Bank AG set a $200.00 price objective on Thermo Fisher Scientific and gave the company a “buy” rating in a research report on Saturday, June 10th. Jefferies Group LLC reiterated a “hold” rating and issued a $175.00 target price on shares of Thermo Fisher Scientific in a report on Wednesday, May 17th. Cantor Fitzgerald began coverage on Thermo Fisher Scientific in a report on Thursday, May 18th. They issued an “overweight” rating and a $194.00 target price on the stock. Barclays PLC restated an “overweight” rating and set a $190.00 price objective (up previously from $175.00) on shares of Thermo Fisher Scientific in a research note on Tuesday, May 9th. Finally, Bank of America Corporation boosted their price objective on Thermo Fisher Scientific from $190.00 to $200.00 and gave the stock a “buy” rating in a research note on Tuesday, May 9th. Three equities research analysts have rated the stock with a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Thermo Fisher Scientific presently has a consensus rating of “Buy” and a consensus target price of $183.47.
In other news, CFO Stephen Williamson sold 2,500 shares of the company’s stock in a transaction that occurred on Monday, June 5th. The shares were sold at an average price of $176.26, for a total transaction of $440,650.00. Following the completion of the sale, the chief financial officer now owns 37,790 shares of the company’s stock, valued at approximately $6,660,865.40. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Marc N. Casper sold 20,000 shares of the company’s stock in a transaction that occurred on Thursday, June 1st. The stock was sold at an average price of $172.79, for a total transaction of $3,455,800.00. Following the sale, the chief executive officer now directly owns 269,279 shares of the company’s stock, valued at approximately $46,528,718.41. The disclosure for this sale can be found here. Insiders sold a total of 28,720 shares of company stock valued at $4,960,764 in the last three months. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.